212 related articles for article (PubMed ID: 34425576)
1. Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein.
Jarahian M; Marstaller K; Banna N; Ahani R; Etemadzadeh MH; Boller LK; Azadmanesh K; Cid-Arregui A; Khezri A; Berger MR; Momburg F; Watzl C
J Innate Immun; 2022; 14(2):135-147. PubMed ID: 34425576
[TBL] [Abstract][Full Text] [Related]
2. The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR.
Marzi A; Akhavan A; Simmons G; Gramberg T; Hofmann H; Bates P; Lingappa VR; Pöhlmann S
J Virol; 2006 Jul; 80(13):6305-17. PubMed ID: 16775318
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.
Favier AL; Gout E; Reynard O; Ferraris O; Kleman JP; Volchkov V; Peyrefitte C; Thielens NM
J Virol; 2016 Jun; 90(11):5256-5269. PubMed ID: 26984723
[TBL] [Abstract][Full Text] [Related]
4. Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization.
Marzi A; Wegele A; Pöhlmann S
Virology; 2006 Sep; 352(2):345-56. PubMed ID: 16777170
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR.
Marzi A; Möller P; Hanna SL; Harrer T; Eisemann J; Steinkasserer A; Becker S; Baribaud F; Pöhlmann S
J Infect Dis; 2007 Nov; 196 Suppl 2(Suppl 2):S237-46. PubMed ID: 17940955
[TBL] [Abstract][Full Text] [Related]
6. A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism.
González-Hernández M; Hoffmann M; Brinkmann C; Nehls J; Winkler M; Schindler M; Pöhlmann S
J Virol; 2018 Jul; 92(13):. PubMed ID: 29669839
[TBL] [Abstract][Full Text] [Related]
7. TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis.
Brunton B; Rogers K; Phillips EK; Brouillette RB; Bouls R; Butler NS; Maury W
PLoS Negl Trop Dis; 2019 Jun; 13(6):e0006983. PubMed ID: 31242184
[TBL] [Abstract][Full Text] [Related]
8. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry.
Tran EE; Nelson EA; Bonagiri P; Simmons JA; Shoemaker CJ; Schmaljohn CS; Kobinger GP; Zeitlin L; Subramaniam S; White JM
J Virol; 2016 Sep; 90(17):7618-27. PubMed ID: 27279622
[TBL] [Abstract][Full Text] [Related]
9. Interactions of LSECtin and DC-SIGN/DC-SIGNR with viral ligands: Differential pH dependence, internalization and virion binding.
Gramberg T; Soilleux E; Fisch T; Lalor PF; Hofmann H; Wheeldon S; Cotterill A; Wegele A; Winkler T; Adams DH; Pöhlmann S
Virology; 2008 Mar; 373(1):189-201. PubMed ID: 18083206
[TBL] [Abstract][Full Text] [Related]
10. Cell-cell contact promotes Ebola virus GP-mediated infection.
Miao C; Li M; Zheng YM; Cohen FS; Liu SL
Virology; 2016 Jan; 488():202-15. PubMed ID: 26655238
[TBL] [Abstract][Full Text] [Related]
11. Ebola Virus Requires Phosphatidylserine Scrambling Activity for Efficient Budding and Optimal Infectivity.
Acciani MD; Lay Mendoza MF; Havranek KE; Duncan AM; Iyer H; Linn OL; Brindley MA
J Virol; 2021 Sep; 95(20):e0116521. PubMed ID: 34319156
[TBL] [Abstract][Full Text] [Related]
12. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
13. Growth-Adaptive Mutations in the Ebola Virus Makona Glycoprotein Alter Different Steps in the Virus Entry Pathway.
Ruedas JB; Arnold CE; Palacios G; Connor JH
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021890
[TBL] [Abstract][Full Text] [Related]
14. Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.
Olejnik J; Forero A; Deflubé LR; Hume AJ; Manhart WA; Nishida A; Marzi A; Katze MG; Ebihara H; Rasmussen AL; Mühlberger E
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331091
[TBL] [Abstract][Full Text] [Related]
15. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB
Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457
[TBL] [Abstract][Full Text] [Related]
16. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
[TBL] [Abstract][Full Text] [Related]
17. MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation.
Yu C; Li S; Zhang X; Khan I; Ahmad I; Zhou Y; Li S; Shi J; Wang Y; Zheng YH
mBio; 2020 Sep; 11(5):. PubMed ID: 32934085
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
19. Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway.
Spence JS; Krause TB; Mittler E; Jangra RK; Chandran K
mBio; 2016 Feb; 7(1):e01857-15. PubMed ID: 26861015
[TBL] [Abstract][Full Text] [Related]
20. Detection of cell-cell fusion mediated by Ebola virus glycoproteins.
Bär S; Takada A; Kawaoka Y; Alizon M
J Virol; 2006 Mar; 80(6):2815-22. PubMed ID: 16501090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
